The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Purchased 20,000 more this morning as price had slid and in anticipation of orders and news flow from ESSKA
The ESSKA Congress, held every two years, is a major event in the pan-European calendar that brings together leading medical specialists, including orthopaedic surgeons, clinicians and scientists. https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/exhibiting-at-18th-esska-conference/201805080700131647N/ Collagen Solutions will be primarily highlighting the recent positive data reported for its most advanced regenerative proprietary product, ChondroMimetic-R, an arthroscopic single-surgery, cost-effective solution for osteochondral defect repair. Earlier this year the Company announced positive eight year follow-on data for ChondroMimetic-R demonstrating durable cartilage regeneration in keyhole knee surgery. These results have allowed Collagen Solutions to begin the submission process to re-establish the CE Mark. Commenting on the conference, Jamal Rushdy CEO said: "We are delighted to be exhibiting at the pre-eminent ESSKA where we will be showcasing ChondroMimetic-R This conference will give us the opportunity to actively engage with specialists and potential partners. Being able to demonstrate the key advantages of ChondroMimetic-R over current therapies within this venue is a key part of our strategy of successfully commercialising ChondroMimetic-R."
Yeah,Hopefully bringing in some more major customers.
Exhibiting at ESSKA !
A few big sells can make this share look like a massive drop. I believe that's all. No bad news or anything, in fact imo we are waiting on good news.
Nice. The CBO can only get his gold if the shares stay at 10p for a while. I like incentives that are aligned with shareholder interests. Confident on COS long term, market is huge and they seem to have the best product soon to come onto the market. It will take time of course, but I can wait for that 10p it's ok.
last Rns was looking positive for COS Director/PDMR Dealing https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/director-pdmr-shareholding/201804110700044898K/ The Company announces that it was notified on 10 April that David Evans, Chairman of the Company, has purchased 3,142,857 ordinary shares in the Company ("Ordinary Shares") at 2.75 pence per Ordinary Share. Following the transaction, David Evans' total beneficial holding in the Company has increased to 42,537,411 Ordinary Shares representing 13.11 per cent. of the issued ordinary share capital of the Company.
...Any one know?
Presentation-26th-February-2018 http://www.piworld.co.uk/2018/03/01/collagen-solutions-cos-investor-presentation-26th-february-2018/
And this is why i believe we will see some big rises in coming months. Also the application for the CE Mark for European approval will be completed soon. Sit tight and reep the benefits. All looking good imo.
21 February 2018 http://www.proactiveinvestors.co.uk/LON:COS/Collagen-Solutions-PLC/company_rns/ Positive Eight-Year Results of ChondroMimetic� Cartilage Repair Clinical Study http://www.proactiveinvestors.co.uk/companies/rns/8318/LSE20180221070004_13540142 Study confirms sustained long-term repair of knee cartilage and improved clinical symptoms Collagen Solutions Plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine , including orthopaedic , dental, wound care , and cardiovascular applications, announces successful results from an eight-year extension clinical study of 15 patients who received ChondroMimetic� implants as an osteochondral scaffold for the repair of cartilage defects in the knee. These positive results have now allowed Collagen Solutions to submit an initial submission for CE Mark. Data highlights * Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage. * Improvement in patient clinical symptoms, including pain, function and activity level after treatment sustained over the eight-year period. * The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient reported outcome measure, showed outcomes following the ChondroMimetic procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies. Backed by these results ChondroMimetic is positioned as the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data. The market There are over 1 million surgical procedures in the U.S. and Europe performed each year to treat cartilage defects of the knee1 , yet current treatments have not demonstrated sustainable efficacy beyond five years post-treatment and /or have limited adoption due to cost and complexity. The current indication target for ChondroMimetic is positioned to address at least 30%-40% of these surgeries once adopted world -wide. Clinical results The results of the ChondroMimetic eight-year follow-up study demonstrated favorable improvement for clinical outcomes of pain, function and activity level . Specifically, patient reported scores from the "Modified Cincinnati Rating System" improved from 64.4 pre-operatively to 80.9, which was a highly statistically significant change (p=0.0065) and represented an 8-year overall grading of 'excellent'. Further the study reported KOOS scores for 5 subscales that were equal to or better than KOOS values reported in the literature for more expensive two-stage cartilage repair technologies (Saris AJSM 2008 and Sari
Needs to shrink more to encourage more buys. Why don't the mm's create a decent market in COS...surely buying/selling is better for the mms as well?
We'll go up incrementally, if the mms narrow the spread a bit. However, sp doing better than i expected on the back of NZ restructuring. Soon be off our BACKS and back on our KNEES again.....lol Good tuck-away- buy for HOLD.....imo
Re share price fall, one should bare in mind that small caps on AIM are often prey to ramping or shorting. Remain invested, averaged down recently and as of today slightly down -5% ish. Spread wide and often the dealers offer poor selling price to small investors. That said, this company has an interesting product and a large potential market so buy and hold for me.
They only fell as a knee jerk reaction to end of year financials.No person in their right mind should have sold in a response to that news, unles automatically done if they fell low. The new CE registration, new product with great results, a huge US market. All good for this year. Strong buy/hold. imo of course.
Peeps also realising the sales delays is just that...a delay. It should come right for next Q....? Also, the director share buy and new CBO...(highly impressive credentials)....suggests this company is getting ready to put some meat on the bones...gla BUY - HOLD.....imo
up 14% already this morning, probably people realising its a potential gold mine here.imo of course.
Reassuring, agree with your analysis and willing to wait for better news. I did wonder if this director was averaging down? Many purchased shares at 5p level so most underwater.
Gotta be a good sign.imo
https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/director-pdmr-shareholding/201804110700044898K/ The Company announces that it was notified on 10 April that David Evans, Chairman of the Company, has purchased 3,142,857 ordinary shares in the Company ("Ordinary Shares") at 2.75 pence per Ordinary Share. Following the transaction, David Evans' total beneficial holding in the Company has increased to 42,537,411 Ordinary Shares representing 13.11 per cent. of the issued ordinary share capital of the Company. BUY - HOLD..........imo
Pal of Jal...
https://www.investegate.co.uk/collagen-sol-plc--cos-/rns/appointment-of-chief-business-officer/201804100700073190K/ Mr. Ruggiero is a performance-driven executive with proven success at all levels of sales and general management in the health care and technology industries. He joins Collagen Solutions from Pearson Clinical Assessments where he served as Senior Vice President of Sales. Previously, Mr. Ruggiero spent 10 years as a senior executive and Board Director in the orthopedic device industry. Under his leadership as Chief Commercial Officer of Hely & Weber Orthopedics and Ossur Americas, the companies posted consistent double-digit revenue growth. As the Chief Sales & Marketing Officer of DJO Global, revenue and share price increased over five-fold. Earlier in his career, Mr. Ruggiero served as CEO of Titan Scan Technologies, an early stage B2B company focused on medical device sterilisation and bio-agent remediation. In addition, Mr. Ruggiero served in various leadership roles of increasing responsibility with GE Healthcare, where he earned his Six Sigma Certification. Mr. Ruggiero is a 'summa cum laude' graduate of St. John's University, where he majored in Interpersonal Communication and Political Science, and earned an MBA from Northwestern University Kellogg Graduate School of Management. He is also completing a Doctoral degree in Organizational Leadership from Creighton University.
Has an impressive record...Rns
I'm sorry but lol??
Lol....!